NorthWest Biotherapeutics Inc (NWBO)

[ae kusterer]

LL at Weill :"

Chiugray

Tuesday, March 22, 2022 7:18:01 PM

Re: exwannabe post# 453400

Post#
453438
of 453474
Clearly your criteria for credibility is incredible. Linda Liau says, "It was statistically significant. The group that got dendritic cell vaccination plus poly-ICLC had a 50% survival rate and now we are the majority of patients are reaching 100 months. And not only survival but really no tumor recurrence." and you pooh pooh her statement.

Understand that LL says this knowing what the NWBO DCVax-L Phase 3 results are. She would only be making this "no recurrence" statement in Feb of 2022 knowing there is corroboration in the DCVax-L trial, that DCVax works. They both use DCVax as the base treatment drug. Therefore, as she represents a world class research and academic institution on cancer treatments, her and her other colleague physicians there, would only continue research using DCVax because they knows it works.

That is one big Clue for us retail investors to recognize (before institutional buying does) that the NWBO DCVax-L Phase 3 trial is successful. And all other treatments (that do not stall cancer recurrence or with high toxicity) shall bow to DCVax."